February 4th 2025
A recap of the FDA submissions and regulatory decisions in urology from January 2025.
The primary end point is 12-month radiographic progression-free survival.
A list of facts and trends to know about the current landscape of urologic cancer management and research in the US.
The data also showed that mortality plateaued in recent years despite declining in years prior.
February 3rd 2025
The incidence of late grade 2 or greater GU toxicity at 5 years was 12.5% among those who did experience acute toxicity vs 7.5% among those who did not.
Oncology Decoded Live! Revolutionizing GU Cancer Care: Applying Cutting-Edge Evidence to Practice
February 14, 2025
Register Now!